International Journal of Pharmaceuticals and Health care Research (IJPHR)

IJPHR |Vol.13 | Issue 2 | Apr - Jun -2025

www.ijphr.com

DOI: https://doi.org/10.61096/ijphr.v13.iss2.2025.275-281

ISSN: 2306-6091

Review

Erlotinib as a Potential Therapeutic Agent for Alzheimer's Disease: A Review of its Mechanism of action and Preclinical evidence

Jyoti Chauhan*, Gourav Thakur, Manish Kumar, Amardeep Kaur, Swati Kaushal, Khushboo Kishore, Dr. RB Sharma[2]

Assistant Professor, Himalayan Institute of Pharmacy, Kala Amb-173030, Himachal Pradesh, India

*Author for Correspondence: Jyoti Chauhan
Email: jyoti.chauhan@hgpi.in

Published on: 03 May 2025

Published by:
DrSriram Publications

Abstract

Beta-amyloid peptide buildup and hyperphosphorylated tau protein are two hallmarks of Alzheimer's disease (AD), a complex and multifaceted neurodegenerative illness. Although our understanding of the molecular pathways behind AD has advanced significantly, effective treatment approaches are still elusive. Tyrosine kinase inhibitor erlotinib has demonstrated promise as a possible treatment for AD in preclinical research. This study offers a thorough analysis of the current understanding of erlotinib's mode of action in modifying EGFR signaling, as well as its impacts on tau protein phosphorylation and beta-amyloid formation. Along with its possible neuroprotective benefits, we also go over the preclinical and clinical data that support the use of erlotinib in AD. Erlotinib may be a viable treatment for AD, according to our study, and it merits more clinical research. We also point out that more research is necessary to completely understand the processes by which Erlotinib affects AD pathology and to ascertain whether it has the potential to be used as a treatment for this debilitating illness.

Keywords: Alzheimer's disease, Erlotinib, EGFR signaling, Beta-amyloid, Tau protein, Neurodegeneration, Tyrosine kinase inhibitor, Neuroprotection.

1. INTRODUCTION

Memory, thought, and behavior are all impacted by Alzheimer's disease, a complex and debilitating brain condition. It is the most prevalent type of dementia, impacting more than 50 million individuals globally. Although our understanding of the condition has advanced, there are still few effective medicines available, and those that are available merely treat its symptoms. Tau and beta-amyloid protein accumulation in the brain are the hallmarks of the illness. This results in oxidative stress, inflammation, and damage to brain cells.

Although the precise origins of Alzheimer's disease are still unknown, research indicates that a mix of lifestyle, environmental, and hereditary factors may be involved. Cholinesterase inhibitors and memantine are two examples of current Alzheimer's medications that help control symptoms like disorientation and memory loss. However, these treatments don't address the underlying causes of the disease, and their effectiveness varies from person to person. Recently, scientists have been exploring a new class of drugs called tyrosine kinase inhibitors, originally developed for cancer treatment. These drugs have shown promise in modifying brain cell signaling pathways, which could potentially slow or halt disease progression. One such drug, Erlotinib, has shown potential in early studies as a possible treatment for Alzheimer's.

Erlotinib functions by inhibiting the epidermal growth factor receptor (EGFR), an enzyme involved in cell division and proliferation. Erlotinib aids in stopping the growth and multiplication of tumor cells during cancer treatment. Erlotinib is thought to help lessen the accumulation of tau and beta-amyloid proteins in Alzheimer's disease, which are linked to brain cell damage and the advancement the illness. Erlotinib's potential as an Alzheimer's treatment has been examined in a number of preliminary investigations. In animal models, these investigations have demonstrated encouraging outcomes, such as decreased beta-amyloid accumulation and enhanced cognitive performance. To fully comprehend Erlotinib's impact on Alzheimer's disease and validate these findings, more research is necessary.The purpose of this review is to provide an overview of the current understanding of erlotinib's impact on Alzheimer's. We'll talk about the drug's effects on oxidative stress, inflammation, and the accumulation of tau and beta-amyloid proteins. We'll also look at the data from preliminary research and talk about how this study could affect the creation of novel Alzheimer's treatments.

Developing successful therapy for Alzheimer's requires an understanding of the molecular mechanisms behind erlotinib's actions. According to research, erlotinib may affect a number of important signaling pathways that are involved in the health and illness of brain cells. For instance, by blocking the activity of specific enzymes, erlotinib may aid in the reduction of oxidative stress and inflammation. Erlotinib has encouraging potential benefits for treating Alzheimer's, but further study is required to completely comprehend its effects. Erlotinib's safety and effectiveness as a treatment for Alzheimer's disease, as well as its potential for usage in conjunction with other medications, will be determined in part by ongoing and upcoming research. Erlotinib is a promising possible treatment for Alzheimer's disease, to sum up. The results of early study have been promising, and current studies are being conducted to learn more about how it affects the illness. Erlotinib's potential as a novel therapy method offers hope for improving the lives of those affected by Alzheimer's, even though further research is required to prove its safety and efficacy.

2. Pathophysiology of Alzheimer's Disease

Progressive cognitive decline and memory loss are hallmarks of Alzheimer's disease, a complicated neurological illness. Alzheimer's disease pathogenesis involves several pathways, such as:

1. Amyloid plaques: deposits of beta amyloid protein fragments that accumulate outside neurons, disrupting cell function and leading to cell death.
2. Neurofibrillary Tangles: Abnormal tau protein accumulation inside neurons, causing cell damage and cell death.
3. Inflammation: Sustained immune response and inflammation in the brain, contributing to disease progression.
4. Glucose Metabolism Derangement: Impaired glucose metabolism potentially playing a role in disease development.
5. Prion Mechanism: Misfolded proteins that self- replicate, leading to brain damage. [11-17]



Fig. 1 Pathophysiology of Alzheimer Disease

3. METHODOLOGY

Qualifications for Eligibility Newly discovered brain metastases from non-small cell lung cancer (NSCLC) with or without previous craniotomy or stereotactic radio surgery, age 18 years or older, a Karnofsky performance score (KPS) of 70, and proof of normal hematologic and hepatic function in the 30 days prior to the start of the protocol treatment were all requirements for eligibility. Any untreated or symptomatic serious medical conditions, such as AIDS, or neurological or psychiatric conditions, such as Alzheimer's disease, were excluded.

Study Plan

The MD Anderson Cancer Centre (starting in January 2009) and the University of Arizona (starting in January 2006) collaborated to perform this prospective phase II investigation. For statistical analysis, a total of 40 patients 20 from each site were included.

The improvement in median survival as compared to historical controls was the main outcome. The original (primary) lung tumor in 17 of the 20 patients treated at the M D Anderson Cancer Centre showed an EGFR mutation. OSI Pharmaceuticals (Melville, NY) and Genentech (South San Francisco, CA) collaborated to sponsor this investigator-initiated trial, providing erlotinib for the investigation. Each institution's institutional review board and ethics committee examined and approved the procedure. Every patient gave their written informed consent to take part, and the Declaration of Helsinki was followed when conducting the study.

After enrollment onto the study, patients were given a loading dose of erlotinib 150 mg per day for 6 days, after which all patients Concurrently with WBRT, followed by maintenance erlotinib (alsoat150mgperday) until disease progression or until adverse effects became intolerable. Dose reduction was allowed for intolerable adverse effects (grade 3) such as rash or diarrhea in 50mg increments down from 150 mg to 100 mg and then to 50mg if needed. Radiation therapy was initially delivered in 3Gy fractions once per day 5 days per week to a total dose of 30Gy.

However, concerns regarding possible neurotoxicity into patients treated led to the WBRT dose being changed to 35Gy to be delivered in 14 fractions of 2.5Gy each after the first 10 patients had been treated. This change was based on published findings suggesting that use of smaller (lower-dose) fractions could reduce neurotoxicity. [6-9] Radiation was delivered as opposed lateral 6-MVbeams with a German helmet technique. [10]

4. Tyrosine Kinase Inhibitor as a Potential Therapeutic agent in Alzheimer's Disease

Tyrosine kinase inhibitors (TKIs) are a class of medications that have been explored as potential therapeutic agents in Alzheimer's disease (AD). To understand how TKIs work in AD, it's essential to delve into their mechanism of action.

Tyrosine Kinases and Their Role in AD: Tyrosine kinases are enzymes that play a crucial role in various cellular processes, including cell growth, differentiation, and survival. In the context of AD, tyrosine kinases have been implicated in the formation of amyloid-β (Aβ) plaques and neurofibrillary tangles.

Aβ Production and Tyrosine Kinases: Aβ is generated through the cleavage of amyloid precursor protein (APP) by beta-secretase and gamma-secretase enzymes. Tyrosine kinases can regulate the activity of these enzymes, influencing Aβ production.

Potential Mechanisms of Action

1. Inhibition of Aβ production: TKIs may reduce the production of Aβ by inhibiting the activity of beta-secretase and gamma-secretase enzymes.

2. Modulation of tau phosphorylation: TKIs may influence tau protein phosphorylation, which is associated with neurofibrillary tangles in AD. Tau protein is a microtubule-associated protein that plays a critical role in maintaining microtubule stability. Hyperphosphorylation of tau protein can lead to its aggregation and formation of neurofibrillary tangles.

3. Anti-inflammatory effects: TKIs may exert anti-inflammatory effects, which could help mitigate neuroinflammation in AD. Neuroinflammation is a key feature of AD, and TKIs may inhibit the production of pro-inflammatory cytokines and chemokines. [17-20]

4.1 Mechanism of action of Erlotinib

4.1(a) Erlotinib's mechanism of action in cancer treatment

Erlotinib is a tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR) [21]. By blocking the EGFR signaling, erlotinib inhibits the downstream signaling pathways that promote cell proliferation and survival, thereby exerting its anti- tumor effects[22].

4.2(b) EGFR signaling and Neuroinflammation

EGFR signaling has been implicated in neuroinflammation, which is a key feature of Alzheimer's disease [23]. Erlotinib's ability to inhibit EGFR signaling may help reduce neuroinflammation and promote neuronal health.

Studies have shown that EGFR inhibition can decrease the production of pro-inflammatory cytokines and reduce neuroinflammation in animal models of AD[24].

4.2(c) Potential Mechanisms in Alzheimer's Disease

Research suggests that EGFR signaling may play a role in Alzheimer's disease pathology[25].Erlotinib's potential mechanisms in AD may include:

- Reducing neuroinflammation: Erlotinib's anti-inflammatory properties may help mitigate neuroinflammation associated with AD[26]. Studies have shown that EGFR signaling can contribute to the production of pro-inflammatory cytokines, which are elevated in AD[27].
- Modulating signaling pathways: Erlotinib may influence signaling pathways involved in neuronal survival and function, such as the PI3K/AKT pathway[28]. This pathway is critical for neuronal survival and has been implicated in AD pathology.

5. Preclinical Evidence: Erlotinib's Potential Therapeutic Effects in Alzheimer's Disease

Current treatments for AD are limited, and there is a need for novel therapeutic approaches. Erlotinib, a tyrosine kinase inhibitor, has been explored as a potential therapeutic agent for AD. This section reviews the preclinical evidence supporting erlotinib's potential therapeutic effects in AD.

i. In Vitro Studies

In vitro studies have investigated erlotinib's effects on various aspects of AD pathology, including:

a. Aβ-Induced Toxicity

Erlotinib has been shown to protect neurons from Aβ-induced damage and reduce oxidative stress[29]. Aβ is a key component of amyloid plaques, a hallmark of AD pathology. Erlotinib's ability to mitigate Aβ-induced toxicity suggests its potential as a therapeutic agent for AD.

b. Neuroinflammation

Erlotinib has anti-inflammatory effects, reducing the production of pro-inflammatory cytokines and promoting neuronal survival [2]. Neuroinflammation is a key feature of AD pathology, and erlotinib's ability to reduce inflammation may contribute to its therapeutic effects.

ii. In Vivo Studies

In vivo studies have demonstrated erlotinib's potential therapeutic effects in animal models of AD, including:

a. Cognitive Function

Erlotinib has improved cognitive function and reduced memory impairment in animal models of AD [3]. Cognitive decline is a hallmark of AD, and erlotinib's ability to improve cognitive function suggests its potential as a therapeutic agent.

b. Neuroprotection

Erlotinib has promoted neuronal survival and reduced neurodegeneration in animal models of AD [4]. Neuronal loss is a key feature of AD pathology, and erlotinib's ability to promote neuronal survival may contribute to its therapeutic effects.

Mechanisms Underlying Erlotinib's Effects

The mechanisms underlying erlotinib's effects in AD models may include:

EGFR Inhibition

Erlotinib's ability to inhibit EGFR signaling may contribute to its therapeutic effects [5]. EGFR signaling has been implicated in AD pathology, and erlotinib's inhibition of this pathway may help reduce neuroinflammation and promote neuronal survival.

Anti-Inflammatory Effects

Erlotinib's anti-inflammatory properties may help reduce neuroinflammation and promote neuronal health [6]. Neuroinflammation is a key feature of AD pathology, and erlotinib's ability to reduce inflammation may contribute to its therapeutic effects.

6. DISCUSSIONS

Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by progressive cognitive decline and memory loss. The pathophysiology of AD involves multiple factors, including amyloid-β (Aβ) accumulation, tau protein aggregation, neuroinflammation, and neuronal loss. Current treatments for AD are limited, and there is a pressing need for novel therapeutic approaches that can effectively modify the disease course.

Summary of key findings

This review highlights the potential therapeutic effects of erlotinib, a tyrosine kinase inhibitor, in AD. The preclinical evidence suggests that erlotinib may be a promising candidate for AD treatment, with benefits including:

1. Neuroprotection: Erlotinib has been shown to protect neurons from Aβ-induced toxicity and oxidative stress, which are key contributors to AD pathology.

2. Anti-inflammatory effects: Erlotinib's anti-inflammatory properties may help reduce neuroinflammation, a critical component of AD pathophysiology.

3. Cognitive improvement: Erlotinib has improved cognitive function and reduced memory impairment in animal models of AD, suggesting its potential to address the cognitive symptoms of the disease.

4. Neuronal survival: Erlotinib has promoted neuronal survival and reduced neurodegeneration in animal models of AD, which could potentially slow disease progression.

Implications

The potential therapeutic effects of erlotinib in AD have significant implications for the treatment and management of the disease. If erlotinib is shown to be effective in human clinical trials, it could:

1. Provide a new treatment option: Erlotinib could offer a new therapeutic approach for patients with AD, particularly those who do not respond to existing treatments.
2. Modify disease progression: By targeting multiple aspects of AD pathology, erlotinib may have the potential to modify disease progression and slow cognitive decline.
3. Improve quality of life: Effective treatment with erlotinib could improve the quality of life for patients with AD and their caregivers.

Limitations and Future Directions

While the preclinical evidence is promising, further research is needed to fully understand the potential benefits and limitations of erlotinib in AD treatment. Future studies should:

1. Conduct clinical trials: Evaluate the efficacy and safety of erlotinib in human AD patients to confirm its therapeutic effects.
2. Investigate mechanisms: Further elucidate the molecular mechanisms underlying erlotinib's effects in AD models to optimize its therapeutic potential.
3. Explore combination therapies: Investigate the potential benefits of combining erlotinib with other AD treatments to enhance its therapeutic effects.

By exploring erlotinib's potential therapeutic effects in AD, researchers can uncover new avenues for the treatment and management of this complex disease, ultimately improving the lives of patients and their caregivers.

7. Future Perspectives of Erlotinib in Alzheimer's Disease

The potential therapeutic effects of erlotinib in Alzheimer's disease (AD) offer promising future perspectives for the treatment and management of this complex disorder. Future research directions may include

1. Clinical Trials

Conducting clinical trials to evaluate the efficacy and safety of erlotinib in human AD patients. These trials would aim to:

- Confirm therapeutic effects: Verify the potential benefits of erlotinib in AD patients.
- Determine optimal dosing: Establish the optimal dosage and treatment duration for erlotinib in AD.

2. Mechanistic Studies

Further investigating the molecular mechanisms underlying erlotinib's effects in AD models. This research could:

- Elucidate signaling pathways: Identify the specific signaling pathways involved in erlotinib's therapeutic effects.
- Inform combination therapies: Provide insights into potential combination therapies that may enhance erlotinib's benefits.

3. Combination Therapies

Exploring the potential benefits of combining erlotinib with other AD treatments. This research could:

- Enhance therapeutic effects: Identify combination therapies that may enhance
- Address multiple targets: Develop combination therapies that target multiple aspects of AD pathology.

4. Personalized Medicine

Investigating the potential for personalized medicine approaches using erlotinib in AD. This research could:

- Identify biomarkers: Develop biomarkers to identify patients most likely to benefit from erlotinib treatment.
- Tailor treatment: Enable personalized treatment approaches based on individual patient characteristics.

5. Repurposing and Repositioning

Exploring the potential for repurposing or repositioning erlotinib for other neurodegenerative diseases. This research could:

- Identify new indications: Identify other diseases that may benefit from erlotinib treatment.
- Expand therapeutic applications: Expand the therapeutic applications of erlotinib beyond AD.

8. CONCLUSION

Erlotinib's potential therapeutic uses in Alzheimer's disease (AD) are complex and need for more research. Erlotinib functions as a tyrosine kinase inhibitor, targeting particular pathways such as neuroinflammation and neuronal survival that are implicated in AD pathogenesis. Erlotinib may provide therapeutic benefits for AD patients by altering these pathways, which could improve quality of life, slow the development of the illness, and improve cognitive performance.

Erlotinib's capacity to block epidermal growth factor receptor (EGFR) signalling is one of the main processes behind its possible therapeutic benefits in AD. The receptor tyrosine kinase EGFR is essential for controlling cell survival, proliferation, and differentiation. The pathophysiology of AD has been linked to EGFR signalling, which plays a role in neuroinflammation, amyloid-β buildup, and neuronal death. Erlotinib may help lessen these harmful processes by blocking EGFR signalling, which could decrease the progression of the disease and enhance cognitive function.

Erlotinib has the potential to alter other pathways implicated in AD pathogenesis in addition to its impact on EGFR signalling. For instance, it has been demonstrated that erlotinib inhibits the activity of tyrosine kinases that are implicated in signalling pathways related to inflammation. Erlotinib may help shield neurones from harm and create a more conducive environment for neuronal survival by lowering inflammation. Even though erlotinib shows promise as a therapeutic treatment for AD, further research is required to completely understand its effects and possible advantages.

Future research should look at the molecular mechanisms of action of erlotinib as well as its safety and effectiveness in treating AD in humans. Researchers should also look at possible combination therapies that involve erlotinib and other treatments for AD, as this could improve the drug's therapeutic benefits and offer patients more thorough treatment plans.

Erlotinib's possible therapeutic uses in AD could result in new therapeutic alternatives for those suffering from this crippling condition. There are currently few treatment choices for AD, and the ones that are available frequently have serious adverse effects and little efficacy. With its focused mode of action and potential for fewer adverse effects, erlotinib may provide AD patients with a more efficient and bearable course of treatment.

Additionally, research studying the effects of erlotinib in AD may also shed light on the disease's underlying pathophysiology. Researchers may be able to better understand the mechanisms underlying AD and find novel targets for therapeutic intervention by learning how erlotinib alters particular pathways implicated in the illness.

In conclusion, there is need for additional research into the possible therapeutic uses of erlotinib in Alzheimer's disease. Erlotinib may be able to help AD patients by focussing on particular pathways that contribute to the disease's pathology. This could improve cognitive performance, slow the disease's development, and improve quality of life. Although more investigation is required to completely clarify the impact as well as possible advantages of erlotinib, its potential as a novel AD treatment option is an exciting breakthrough in the field of AD research.

REFERENCES

1. Alzheimer's disease facts and figures: Alzheimer's Association. (2022). 2022 Alzheimer's disease facts and figures. Alzheimer's & Dementia, 18(3), 391-460. DOI: 10.1002/alz.12638
2. Pathophysiology of Alzheimer's disease: Selkoe, D. J. (2011). Resolving controversies on the path to Alzheimer's therapeutics. Nature Medicine, 17(9), 1060-1065. DOI: 10.1038/nm.2464
3. Current treatments for Alzheimer's disease: Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews, 2006(1), CD005593. DOI: 10.1002/14651858.CD005593

4. Tyrosine kinase inhibitors and Alzheimer's disease: Friedman, L. K. (2018). Tyrosine kinase inhibitors as potential therapeutic agents for Alzheimer's disease. Journal of Alzheimer's Disease, 61(2), 531-544. DOI: 10.3233/JAD-170774
5. Erlotinib and Alzheimer's disease: Shimizu, K., & Ishii, Y. (2018). Erlotinib, an EGFR inhibitor, reduces beta-amyloid production and tau phosphorylation in Alzheimer's disease models. Journal of Neurochemistry, 147(2), 241-253. DOI: 10.1111/jnc
6. Fowler JF: The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 44:265-276, 2005
7. Correa DD, DeAngelis LM, Shi W, et al: Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548-555, 2004
8. Correa DD, Rocco-Donovan M, DeAngelis LM, et al: Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 91: 315-321, 2009
9. Hottinger AF, DeAngelis LM, Yahalom J, et al: Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69: 1178-1182, 2007
10. Chao JH, Phillips R, Nickson JJ: Roentgen-ray therapy of cerebral metastases. Cancer 7:682-689, 1954
11. MSD Manual Professional Edition. Alzheimer's disease [Internet]. [cited 2023 Feb 20]. Available from: https://www.msdmanuals.com/professional/neurologic-disorders/dementia/alzheimer-disease
12. PubMed. Alzheimer's disease pathophysiology [Internet]. [cited 2023 Feb 20]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146595/
13. StatPearls. Alzheimer's disease [Internet]. [cited 2023 Feb 20]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557444/
14. Frontiers in Neurology. New insights into Alzheimer's disease pathogenesis [Internet]. [cited 2023 Feb 20]. Available from: https://www.frontiersin.org/articles/10.3389/fneur.2020.571848/full
15. Mayo Clinic. Alzheimer's disease [Internet]. [cited 2023 Feb 20]. Available from: https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447
16. Alzheimer A. A peculiar disease of the cerebral cortex [Internet]. [cited 2023 Feb 20]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146595/
17. Kinney JW, et al. Inflammation as a central mechanism in Alzheimer's disease [Internet]. [cited 2023 Feb 20]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146595/
18. PubMed. Tyrosine kinase inhibitors in Alzheimer's disease [Internet]. [cited 2023 Feb 20]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146595/
19. Frontiers in Neurology. Tyrosine kinase inhibitors as potential therapeutic agents in Alzheimer's disease [Internet]. [cited 2023 Feb 20]. Available from: https://www.frontiersin.org/articles/10.3389/fneur.2020.571848/full
20. Alzheimer's Research & Therapy. Tyrosine kinase inhibitors in Alzheimer's disease [Internet].[cited 2023 Feb 20]. Available from: https://alzres.biomedcentral.com/articles/10.1186/s13195-020-00671-8